Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE versus DYNA HEX 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE versus DYNA HEX 2.
ACTICLATE vs DYNA-HEX 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
Chlorhexidine gluconate is a cationic bisbiguanide antiseptic that disrupts microbial cell membranes by binding to negatively charged bacterial cell walls, causing leakage of intracellular contents and cell death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, fungi, and some viruses.
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
1-2 mg IV/IM every 4-6 hours as needed for anxiety, up to 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (CrCl 30-50 mL/min).
2-4 hours; prolonged in renal impairment (up to 10-12 hours in anuria).
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Primarily renal (70-80% unchanged) with minor biliary excretion (<5%) and fecal elimination (<5%).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic